Bristol-Myers Squibb (BMS) has reported that the Phase III CheckMate -548 clinical study of an Opdivo (nivolumab) combination in glioblastoma multiforme (GBM) patients has failed to meet the primary endpoint of progression-free survival (PFS).

Opdivo is an immune checkpoint inhibitor of programmed death-1 (PD-1). It uses the body’s immune system to restore immune response against cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The CheckMate -548 trial assessed the combination of Opdivo plus current standard of care comprising temozolomide and radiation therapy compared to standard of care alone.

Newly diagnosed patients with O6-methylguanine-DNA methyltransferase (MGMT)-methylated GBM have been enrolled into the randomised, multi-centre trial.

The trial’s primary endpoints are PFS and overall survival (OS), while secondary endpoints include investigator-assessed PFS and OS up to two years.

“We are continuing to evaluate the benefit of the addition of Opdivo to the standard of care treatment regimen may bring to patients suffering from GBM.”

After the study failed to meet the PFS primary endpoint, the data monitoring committee suggested that it can continue to allow the OS data to mature.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bristol-Myers Squibb Oncology Development head Fouad Namouni said: “Though CheckMate -548 did not show statistically significant improvement in progression-free survival, we are continuing to evaluate the benefit of the addition of Opdivo to the standard of care treatment regimen may bring to patients suffering from GBM, an extremely aggressive and difficult disease to treat.

“We look forward to seeing the overall survival data when they are available.”

In June, the company announced that Opdivo did not meet the primary endpoint of overall survival in the Phase III CheckMate -459 study, compared to sorafenib, in unresectable hepatocellular carcinoma (HCC) patients.

BMS is developing Opdivo as a monotherapy and combination treatment for a wide range of cancers.

The drug already holds multiple approvals, including for the treatment of metastatic melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and small cell lung cancer (SCLC).